'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Ajanta Pharma has increased 14.08% to Rs 1353.73 crore. Operating profit margin has declined from 26.22% to 24.22%, leading to 5.35% rise in operating profit to Rs 327.83 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.58% to 16.64%. Purchase of finished goods cost rose from 3.89% to 4.07%. Employee cost increased from 22.16% to 24.24%. Other expenses rose from 29.96% to 29.98%.
Other income rose 204.62% to Rs 59.34 crore. PBIDT rose 17.09% to Rs 387.17 crore. Provision for interest fell 43.69% to Rs 3.39 crore. Loan funds rose to Rs 245.89 crore as of 30 September 2025 from Rs 32.79 crore as of 30 September 2024. Inventories declined from Rs 845.66 crore...
Pleaselogin & subscribe to view the full report.
More Reports
|
|